Pharmacogenomics
DOI:
https://doi.org/10.47957/ijpda.v12i1.580Keywords:
Pharmacogenomics, genomics, Applications, PharmacologyAbstract
Pharmacogenomics represents a cutting-edge fusion of pharmacology, the intricate science of drugs, and genomics, the study of genes. This innovative discipline aims to craft personalized and secure medications, custom-tailored to an individual's unique genetic composition. Within the context of the burgeoning paradigm of personalized medicine (PM), the application of pharmacogenetics and pharmacogenomics (PGx) assumes an escalating significance. In the realm of clinical trials, the incorporation of PGx represents an adjunctive tool meriting consideration, fostering an enhanced comprehension of the efficacy and safety profiles of novel pharmaceutical entities. Foreseeing the near future, pharmacogenomics holds the promise of facilitating the formulation of tailor-made therapeutics to address pervasive health challenges such as neurodegenerative disorders, cardiovascular ailments, HIV, cancer, asthma, and other conditions. This review article covers the overall Pharmacogenomics.
Downloads
References
Rollinson V.,Turner R.M., Pirmohamed M. Pharmacogenomics: An overview ,The Pharmaceutical Journal 2017. Page-1-13.
Maruf, A.A.; Aziz, M.A. The Potential Roles of Pharmacists in the Clinical Implementation of Pharmacogenomics. Pharmacy 2023, 11, 180. https://doi.org/10.3390/ pharmacy11060180
Shukla R. Pharmacogenomics: Overview, Applications, and Recent Developments [Internet]. Drug Design - Novel Advances in the Omics Field and Applications. IntechOpen; 2021. Available from: http://dx.doi.org/10.5772/intechopen.93737
Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, et al. Evaluation of genetic factors for warfarin dose prediction. Clinical Medicine & Research. 2007;5(1):8-16
Wattanachai N, Kaewmoongkun S, Pussadhamma B, Makarawate P, Wongvipaporn C, Kiatchoosakun S, et al. The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients. European Journal of Clinical Pharmacology. 2017;73(8):973-980
Cha PC, Zembutsu H, Takahashi A, Kubo M, Kamatani N, Nakamura Y. A genome-wide association study identifies SNP in DCC is associated with gallbladder cancer in the Japanese population. Journal of Human Genetics. 2012;57(4):235-237
Chadwick R, Ten Have H, Meslin EM. The Sage Handbook of Health Care Ethics. Sage Publications; 2011
Alsanosi SM, Skiffington C, Padmanabhan S. Pharmacokinetic pharmacogenomics. In: Handbook of Pharmacogenomics and Stratified Medicine. 2014. pp. 341-364
Patil J. Pharmacogenetics and pharmacogenomics: A brief introduction. Journal of Pharmacovigilance. 2015;2:3-4
Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacological Reviews. 2011;63(2):437-459
Xie HG, Frueh FW. Pharmacogenomics steps toward personalized medicine. Future Medicine. 2005:325-337.
Akhare N. A. , Joshi S. S.,Pharmacogenomics: The Role of Genetic Variations in Drug Response, Journal of emerging technologies and innovative research, (10)2023 page- 307-316.
Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409(6822):928-934
Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: Translating science into practice. Clinical Pharmacology and Therapeutics. 2012;92(4):467-475
Pirmohamed M. Pharmacogenetics and pharmacogenomics. British Journal of Clinical Pharmacology. 2001;52(4):345
Handa M, Sharma A, Verma RK, Shukla R. Polycaprolactone based nano-carrier for co-administration of moxifloxacin and rutin and its in-vitro evaluation for sepsis. Journal of Drug Delivery Science and Technology. 2019;54:101286
Roses AD. Pharmacogenetics and the practice of medicine. Nature. 2000;405(6788):857-865
Rollinson V, Turner R, Pirmohamed M. Pharmacogenomics for Primary Care: An Overview. Genes. 2020; 11(11):1337. https://doi.org/10.3390/genes11111337
Vizirianakis IS. Challenges in current drug delivery from the potential application of pharmacogenomics and personalized medicine in clinical practice. Current Drug Delivery. 2004;1(1):73-80
Kalow W. Pharmacogenetics and pharmacogenomics: Origin, status, and the hope for personalized medicine. The Pharmacogenomics Journal. 2006;6(3):162-165
Hicks JK, McLeod HL. Pharmacogenetics and pharmacogenomics. In: Genomic and Precision Medicine. Academic Press; 2017. pp. 89-107
Shastry BS. Pharmacogenetics and the concept of individualized medicine. The Pharmacogenomics Journal. 2006Jan;6(1):16-21
Agustriawan DA, Sumarpo AN, Parikesit AA, Nurdiansyah RI, Adisurja GP, Putra AR. In silico study of miRNA-regulated IQ motif containing GTpase-activating protein family in liver cancer. Asian Journal of Pharmaceutical and Clinical Research. 2018;11:98-101
Hocevar K, Risti c S and Peterlin B ´ (2019) Pharmacogenomics of Multiple Sclerosis: A Systematic Review. Front. Neurol. 10:134. doi: 10.3389/fneur.2019.00134.
Kim S, Yun YM, Chae HJ, Cho HJ, Ji M, Kim IS, et al. Clinical pharmacogenetic testing and application: Laboratory medicine clinical practice guidelines.
Annals of Laboratory Medicine. 2017;37(2):180-193. Voora D, Ginsburg GS. Clinical application of cardiovascular pharmacogenetics. Journal of the American College of Cardiology. 2012;60(1):9-20
Ridker PM, Pare G, Parker AN, Zee RY, Miletich JP, Chasman DI.Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18245 initially healthy women from the Women’s Genome Health Study. Circulation. Cardiovascular Genetics.2009;2(1):26-33
Maggo SD, Kennedy MA, Clark DW. Clinical implications of pharmacogenetic variation on the effects of statins. Drug Safety. 2011;34(1):1-9
Xiong Z, Ma A, Chen H. JAK3 inhibitors in organ transplantation and autoimmune disease. Recent Patents on Inflammation & Allergy Drug Discovery. 2010;4(1):75-81
Säemann MD, Zeyda M, Stulnig TM,Böhmig GA, Wekerle T, Hörl WH, et al. Janus kinase?3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transplant International. 2004;17(9):481-489
Kabbani D, Akika R, Wahid A, Daly AK, Cascorbi I and Zgheib NK (2023), Pharmacogenomics in practice: a review and implementation guide. Front. Pharmacol. 14:1189976. doi: 10.3389/fphar.2023.1189976
Haan C, Rolvering C, Raulf F, Kapp M, Drückes P, Thoma G, et al. Jak1 has a dominant role over Jak3 in signal transduction through ?c-containing cytokine receptors. Chemistry & Biology. 2011;18(3):314-323
Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends in Molecular Medicine. 2001;7(5):201-204
Shah NJ. Regulation of gene expression. In: Introduction to Basics of Pharmacology and Toxicology. Vol. 1: General and Molecular Pharmacology: Principles of Drug Action. 2019. p. 381
Mini E, Nobili S. Pharmacogenetics: Implementing personalized medicine. Clinical Cases in Mineral and Bone Metabolism. 2009;6(1):17
Manolio TA, Collins FS. The HapMap and genome-wide association studies in diagnosis and therapy. Annual Review of Medicine. 2009;60:443-456
Webb A, Hancock JM, Holmes CC. Phylogenetic inference under recombination using Bayesian stochastic topology selection.Bioinformatics. 2009;25(2):197-203
Peacock E, Whiteley P. Perlegen sciences, inc. Pharmacogenomics. 2005;6(4):439-442
Sadee, Wolfgang & Wang, Danxin & Hartmann, Katherine & Toland, Amanda. (2023). Pharmacogenomics: Driving Personalized Medicine. Pharmacological Reviews. 75. PHARMREV-AR. 10.1124/pharmrev.122.000810.
Slate J, Gratten J, Beraldi D, Stapley J, Hale M, Pemberton JM. Gene mapping in the wild with SNPs: guidelines and future directions. Genetica. 2009;136(1):97-107
Dean L. Azathioprine therapy and TPMT and NUDT15 genotype. In: Pratt VM, McLeod HL, Rubinstein WS, et al., editors. Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012
Geeleher P, Zhang Z, Wang F, Gruener RF, Nath A, Morrison G, et al. Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies. Genome Research. 2017;27(10):1743-1751
Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drughypersensitivity:Pharmacogenetics and clinical syndromes. The Journal of Allergy and Clinical Immunology. 2011;127(3):S60-S66
Trost JC, Lange RA. Treatment of acute coronary syndrome: Part 2: ST-segment elevation myocardial infarction. Critical Care Medicine. 2012;40(6):1939-1945
Wichmann S, Færk G, Bundgaard JR, Gätke MR. Patients with prolonged effect of succinylcholineor mivacurium had novel mutations in the butyrylcholinesterase gene. Pharmacogenetics and Genomics. 2016;26(7):351-356
Sim E, Laurieri N. Isoniazid induced toxicity: Systemic lupus erythematosus. Journal of Drug Design and Research. 2018;49:51
Kamali F, Wynne H. Pharmacogenetics of warfarin. Annual Review of Medicine. 2010;61:63-75.
Chasman DI, Ridker PM. Pharmacogenetics: The outlook for genetic testing in statin therapy. Nature Clinical Practice. Cardiovascular Medicine. 2005;2(1):2-3
Bienfait, K., Chhibber, A., Marshall, J. C., Armstrong, M., Cox, C., Shaw, P. M., & Paulding, C. (2022). Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG). Human genetics, 141(6), 1165–1173. https://doi.org/10.1007/s00439-021-02282-3
Published
How to Cite
Issue
Section
Copyright (c) 2024 Pooja Sharma, Ritu Rani, Ajeet Pal Singh , Amar Pal Singh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
